US Market Entry BRAHMS USA is the US arm of a global biomarker leader focused on diagnostics for life threatening diseases. There is an opportunity to accelerate US market entry by building hospital and clinical lab partnerships, leveraging patent protected products and the company's international distribution. Offer to provide local regulatory support, validation studies, and commissioning services to speed adoption.

Channel Expansion The company already sells to hospitals and laboratories through global networks. In the US market there is potential to add regional distributors, value added resellers and service partners to grow footprint, with emphasis on training and after sales support.

Licensing Potential With patent protected products and a track record of licensing, there is room for co development of new biomarker tests or diagnostic panels for the US market. Target partnerships with diagnostics firms for exclusive rights or revenue share, leveraging the company's R&D and regulatory pathways.

Competitive Positioning Operating alongside large players indicates a need for differentiated value propositions such as niche biomarkers or rapid deployment solutions for hospital labs. Position as a regional integration partner to complement existing global distributors and expand US workflow coverage.

Growth Readiness The US subsidiary represents an early stage entry with potential for bundles that combine instruments, reagents, service contracts, and regulatory compliance support. Propose offerings that include installation, training, calibration, and data management or LIMS integration to reduce lab onboarding time.